CVSC: AI 评分 46/100 — AI 分析 (4月 2026)

Cardiovascular Sciences, Inc. focuses on developing medical products, including anti-adhesion technology and pyruvate therapy. The company aims to address critical needs in cardiac care and surgical outcomes.

Key Facts: AI Score: 46/100 Sector: Consumer Cyclical

公司概况

概要：

Cardiovascular Sciences, Inc. is a technology company focused on developing medical products, including anti-adhesion technology, pyruvate therapy, thromboresistant coatings, human vascular tissue equivalents, and aortic catheters. The company targets unmet needs in cardiac trauma and surgical outcomes, operating within the consumer cyclical sector.

CVSC是做什么的？

Cardiovascular Sciences, Inc., formerly Beverly Hills Weight Loss and Wellness, Inc., was re-established in May 2006 with a focus on developing medical products aimed at improving cardiac care and surgical outcomes. The company's core offerings include Anti Adhesion Technology products designed to prevent post-surgical scarring, addressing a significant concern in surgical procedures. Another key product is Pyruvate Therapy, a patented method intended for treating patients suffering from cardiac trauma, such as ischemic reperfusion injury, heart failure, and bypass surgery. In addition to these therapies, Cardiovascular Sciences is developing a Thromboresistant Coating to prevent blood clot formation on medical devices, enhancing their safety and efficacy. The company is also working on a biocompatible Human Vascular Tissue Equivalent for artery replacement during heart surgeries, offering a potential alternative to traditional methods. Furthermore, Cardiovascular Sciences holds patents for Aortic Catheters, contributing to advancements in cardiovascular procedures. Based in Orlando, Florida, the company aims to innovate and provide solutions in the medical device and cardiac care sectors.

CVSC的投资论点是什么？

Cardiovascular Sciences, Inc. presents a speculative investment opportunity within the medical technology sector, focusing on innovative solutions for cardiac care and surgical outcomes. The company's patented Pyruvate Therapy and Anti Adhesion Technology represent potential value drivers, addressing unmet needs in cardiac trauma and post-surgical recovery. However, the company's market capitalization of $0.00B and negative beta of -93.20 indicate high volatility and potential risks. Growth catalysts include successful clinical trials and regulatory approvals for its key products, particularly Pyruvate Therapy. The development and commercialization of its Thromboresistant Coating and Human Vascular Tissue Equivalent could also drive future growth. Investors should closely monitor the company's progress in securing partnerships, funding, and market adoption of its technologies. The OTC market listing introduces additional risks related to liquidity and disclosure.

CVSC在哪个行业运营？

Cardiovascular Sciences, Inc. operates within the medical device and technology sector, which is characterized by constant innovation and regulatory scrutiny. The market for cardiac care and surgical solutions is substantial, driven by an aging population and increasing prevalence of cardiovascular diseases. Companies in this sector face intense competition, requiring them to demonstrate clinical efficacy and secure regulatory approvals to gain market share. Cardiovascular Sciences, Inc. aims to differentiate itself through its patented technologies and focus on unmet needs in cardiac trauma and surgical outcomes.

Personal Products & Services

Consumer Cyclical

CVSC有哪些增长机遇？

Expansion of Pyruvate Therapy: Cardiovascular Sciences, Inc. has the opportunity to expand the application of its patented Pyruvate Therapy for treating various cardiac conditions, including ischemic reperfusion injury and heart failure. The market for cardiac therapeutics is substantial, estimated to reach billions of dollars annually. Successful clinical trials and regulatory approvals could drive significant revenue growth for the company. Timeline: Ongoing clinical trials with potential for commercialization within 3-5 years.
Commercialization of Anti Adhesion Technology: The company's Anti Adhesion Technology products have the potential to address a significant market need in preventing post-surgical scarring. The market for anti-adhesion products is growing, driven by increasing surgical procedures and demand for improved patient outcomes. Successful commercialization of these products could generate substantial revenue for Cardiovascular Sciences, Inc. Timeline: Potential for market entry within 2-3 years following regulatory approvals.
Development of Thromboresistant Coating: Cardiovascular Sciences, Inc.'s Thromboresistant Coating technology aims to prevent blood clot formation on medical devices, enhancing their safety and efficacy. The market for thromboresistant coatings is expanding, driven by the increasing use of medical devices in cardiovascular procedures. Successful development and commercialization of this technology could provide a competitive advantage. Timeline: Product development and testing ongoing, with potential for commercialization within 3-5 years.
Advancement of Human Vascular Tissue Equivalent: The company's development of a biocompatible Human Vascular Tissue Equivalent for artery replacement during heart surgeries represents a significant innovation in cardiovascular surgery. The market for vascular grafts and replacements is substantial, driven by the increasing prevalence of cardiovascular diseases. Successful development and clinical validation of this technology could lead to significant market opportunities. Timeline: Long-term development project with potential for clinical trials within 5-7 years.
Strategic Partnerships and Licensing Agreements: Cardiovascular Sciences, Inc. can pursue strategic partnerships and licensing agreements with larger medical device companies to accelerate the development and commercialization of its technologies. Collaborations with established players in the industry can provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. Timeline: Ongoing efforts to establish partnerships and licensing agreements.

Cardiovascular Sciences, Inc. focuses on developing medical products for cardiac care and surgical outcomes.
The company's product portfolio includes Anti Adhesion Technology, Pyruvate Therapy, and Thromboresistant Coating.
Cardiovascular Sciences, Inc. operates in the consumer cyclical sector, specifically within personal products and services.
The company's market capitalization is $0.00B, indicating a micro-cap status.
Cardiovascular Sciences, Inc. was formerly known as Beverly Hills Weight Loss and Wellness, Inc.

CVSC提供哪些产品和服务？

Develop Anti Adhesion Technology products to prevent post-surgical scarring.
Pioneer Pyruvate Therapy, a patented method for treating cardiac trauma patients.
Create Thromboresistant Coating to prevent blood clot formation on medical devices.
Develop a biocompatible Human Vascular Tissue Equivalent for artery replacement.
Patent Aortic Catheters for cardiovascular procedures.
Focus on medical product innovation in the cardiovascular space.

CVSC如何赚钱？

Develop and patent medical technologies.
License or sell patented technologies to medical device companies.
Generate revenue through product sales upon regulatory approval.
Pursue strategic partnerships for product development and distribution.

Hospitals and surgical centers.
Cardiologists and cardiovascular surgeons.
Medical device manufacturers.
Patients undergoing cardiac procedures.

Patented technologies like Pyruvate Therapy.
Specialized expertise in cardiovascular medical products.
Potential for first-mover advantage in niche markets.
Proprietary Anti Adhesion Technology.

什么因素可能推动CVSC股价上涨？

Upcoming: Clinical trial results for Pyruvate Therapy.
Upcoming: Regulatory approval decisions for Anti Adhesion Technology.
Ongoing: Strategic partnerships with medical device companies.
Ongoing: Development of Thromboresistant Coating.
Ongoing: Advancement of Human Vascular Tissue Equivalent.

CVSC的主要风险是什么？

Potential: Clinical trial failures for key products.
Potential: Regulatory delays or rejections.
Ongoing: Competition from established medical device companies.
Ongoing: Limited financial resources.
Ongoing: OTC market listing and associated risks.

CVSC的核心优势是什么？

Proprietary technologies in cardiac care.
Patented Pyruvate Therapy for cardiac trauma.
Focus on unmet needs in surgical outcomes.
Potential for innovation in medical devices.

CVSC的劣势是什么？

Limited financial resources.
Dependence on regulatory approvals.
Small market capitalization.
OTC market listing.

CVSC有哪些机遇？

Strategic partnerships with medical device companies.
Expansion of Pyruvate Therapy applications.
Commercialization of Anti Adhesion Technology.
Development of new cardiovascular products.

CVSC面临哪些威胁？

Competition from established medical device companies.
Regulatory hurdles and clinical trial failures.
Limited access to capital.
Economic downturn affecting healthcare spending.

CVSC的竞争对手是谁？

Arvelle Therapeutics — Focuses on CNS disorders. — (ARVLF)
Asap Group Inc. — Provides staffing solutions. — (ASAPQ)
Bon-Ton Stores Inc. — Operates department stores. — (BONTQ)
iBio, Inc. — Develops plant-based biopharmaceuticals. — (IBGR)
Kongji International Holdings Ltd — Operates in the education sector. — (KGJI)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Larry Hooper
Headquarters: Heathrow, US
Founded: 2001

AI Insight

AI analysis pending for CVSC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cardiovascular Sciences, Inc. do?

Cardiovascular Sciences, Inc. is a technology company focused on developing medical products for cardiac care and surgical outcomes. The company's core offerings include Anti Adhesion Technology products designed to prevent post-surgical scarring, Pyruvate Therapy for treating cardiac trauma, Thromboresistant Coating to prevent blood clot formation, a Human Vascular Tissue Equivalent for artery replacement, and patented Aortic Catheters. The company aims to innovate and provide solutions in the medical device and cardiac care sectors.

What do analysts say about CVSC stock?

As of 2026-03-17, formal analyst ratings for Cardiovascular Sciences, Inc. (CVSC) are unavailable, likely due to its OTC listing and small market capitalization. Given the lack of analyst coverage, investors should conduct their own thorough due diligence, focusing on the company's technology, clinical trial progress, regulatory pathway, and financial resources. The speculative nature of the stock requires careful assessment of both potential upside and significant risks.

What are the main risks for CVSC?

The main risks for Cardiovascular Sciences, Inc. include clinical trial failures, regulatory hurdles, competition from established medical device companies, limited financial resources, and the risks associated with its OTC market listing. Clinical trial failures could significantly impact the company's product pipeline and future prospects. Regulatory delays or rejections could hinder the commercialization of its technologies. Competition from larger companies with greater resources poses a significant challenge. The OTC listing introduces risks related to liquidity, disclosure, and potential price manipulation.